A very good demand environment has led Aspo to upgrade its 2021 EBIT guidance to EUR 30-36m, the midpoint being 6.
Ferronordic will report its Q2 results on 12 August.
NoHo released June sales figures on 13 July with clearly positive operating cash flows.
BankNordik's Q2 2021 profit before loan losses was DKK 47m, DKK 3m (7%) above our estimate, and it reported better-than-expected lending gro...
Redeye comments on Imint’s newly signed agreement with a European customer.
CapMan's net sales in Q2 amounted to EUR 11.9m, in line with our estimates and consensus (EUR 11.
Aspo now guides EUR 30-36m in FY ’21 EBIT The guidance range midpoint is a positive surprise compared to the EUR 31.
Acquisition of CrazyLabs and Ghost Ship Games stand out Embracer announced a total of 8 new acquisit...
Redeye provides a Q2'21 preview and quarterly estimates for Thunderful Groups 2021E financial year.
Redeye raises its forecasts and Base case for Bredband2 following a solid Q2 report, where EBIT beat our forecast by 15%.
There’s downward pressure from the late profitability peak Suominen’s Q1 marked a record high profit...
Group results quite in line with our expectations Detection Technology reported its Q2 results, whic...
Q2 results entailed visible cost synergies Bredband2’s Q2 results were solid.
God omsättning men svagare marginal Infrea redovisade en omsättningsökning på 27,8%, varav förvärvad...
Redeye will likely raise its forecasts and Base case following a solid Q2 report, with EBIT beating ...
Redeye endorses Spago appointing Paul Hargreaves as Chief Development Officer as the company’s Tumorad project approaches the clinical stage...
Talenom reported Q2 figures quite in line with expectations.
Talenom reported 30% y/y sales growth in Q2 21. Organic growth continued to recover and represented ...
Redeye thinks the Q2 report from FlexQube was strong and shows that the company is solidly back on t...
Redeye endorses and is encouraged by IRRAS’ financing deal of some EUR 10m with EIB.
Redeye takes a positive stance to ADDvise’s acquisition of Medisuite.
Tufft jämförelseår Omsättningen steg 5% till 903 mkr (859), men var under vår förväntan om 1033 mkr.
ARR-tillväxt avslöjar operationell medvind Nettoomsättningen var 22 mkr vilket är i linje med våra estimat och motsvarade en tillväxt om 20%...
Redeye raises its valuation on Xbrane following the positive outcome of its phase III study Xplore.
Q2e EBITDA of USD 16m Based on the monthly production updates, we estimate Tethys’ Q2 working intere...
Medcap reported a better Q2 versus our estimates, attributable to a strong performance in the Medtech segment with Abilia showing a robust r...
We expect Netcompany's solid performance continued in Q2, which may trigger a positive revision to i...
Q2 drivet av förvärv och fortsatta Covid-19-tester För Q2 2021 ökade Addlife omsättningen med 82% ti...
